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The potent immunomodulatory activities displayed bymesenchymal stromal cells (MSCs)
have motivated their application in hundreds of clinical trials to date. In some countries,
they have subsequently been approved for the treatment of immune disorders such as
Crohn’s disease and graft-versus-host disease. Increasing evidence suggests that their
main mechanism of action in vivo relies on paracrine signaling and extracellular vesicles.
Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) play a prominent
role in intercellular communication by allowing the horizontal transfer of microRNAs,
mRNAs, proteins, lipids and other bioactive molecules between MSCs and their targets.
However, despite the considerable momentum gained by MSC-EV research, the precise
mechanism bywhichMSC-EVs interact with the immune system is still debated. Available
evidence is highly context-dependent and fragmentary, with a limited number of reports
trying to link their efficacy to specific active components shuttled within them. In this
concise review, currently available evidence on the molecular mechanisms underlying
the effects of MSC-EV cargo on the immune system is analyzed. Studies that pinpoint
specific MSC-EV-borne mediators of immunomodulation are highlighted, with a focus on
the signaling events triggered by MSC-EVs in target immune cells. Reports that study the
effects of preconditioning or “licensing” in MSC-EV-mediated immunomodulation are also
presented. The need for further studies that dissect the mechanisms of MSC-EV cargo
in the adaptive immune system is emphasized. Finally, the major challenges that need to
be addressed to harness the full potential of these signaling vehicles are discussed, with
the ultimate goal of effectively translating MSC-EV treatments into the clinic.
Keywords: mesenchymal stromal cells, extracellular vesicles, immune system, cell therapy, regenerative
medicine, stem cells, paracrine signaling, immunomodulation




Mesenchymal stromal cells (MSCs) are a heterogeneous
population of non-hematopoietic, fibroblast-like adult
progenitor cells, which can be isolated from a variety of
tissue sources (Hass et al., 2011; Samsonraj et al., 2017). MSCs
can self-renew and are multipotent, given their ability to
differentiate into adipocytes, chondrocytes, and osteocytes in
vitro (Dominici et al., 2006). MSCs’ ease of expansion, together
with their tissue repair and immunotherapeutic capabilities, have
motivated their application in hundreds of clinical trials to date
and their subsequent approval in some countries as therapeutic
agents for several immune disorders, such as Crohn’s disease and
graft-versus-host disease (Galderisi et al., 2016; Najar et al., 2016;
Galipeau and Sensébé, 2018).
MSCs display potent immunosuppressive and anti-
inflammatory activities, as well as low immunogenicity (Gao
et al., 2016). They regulate the innate and adaptive immune
systems, and target virtually all immune populations. MSCs
suppress lymphocyte proliferation and activation, reduce
cytokine secretion and cytotoxicity and induce peripheral
tolerance and regulatory cell expansion (Di Nicola et al., 2002; Le
Blanc et al., 2003; Zhao et al., 2016). They also hinder dendritic
cell maturation and activation and polarize proinflammatory
M1 toward anti-inflammatory M2 macrophages (Németh et al.,
2009; Spaggiari et al., 2009).
Migration, engraftment and subsequent differentiation into
target cells were initially considered the main mechanisms
by which MSCs exert their therapeutic effects in regenerative
applications. However, paracrine signaling is currently regarded
as the primarymode of action ofMSCs (Bi et al., 2007; Di Trapani
et al., 2016; Vizoso et al., 2017; Ferreira et al., 2018). Indeed,
the recent proposal to rename MSCs to “medicinal signaling
cells” reflects the paradigm shift in the conception of their main
mechanism of action in vivo, which is not multipotency but
rather the production of trophic factors and bioactive molecules
(Caplan, 2017). Furthermore, engraftment following infusion in
recipient organisms is rare. It has been reported that MSCs are
trapped in the lungs’ microvasculature and are cleared within
24 h (Eggenhofer et al., 2012).
The secretome of MSCs encompasses a wide array of
factors, including cytokines, chemokines, growth factors, and
extracellular matrix proteins. Among the main candidates
of MSCs’ immunomodulatory effects are indoleamine 2,3-
dioxygenase 1, prostaglandin E2 (PGE2), hepatocyte growth
factor, transforming growth factor beta 1, TNF-alpha induced
protein 6 (TSG-6) andmajor histocompatibility complex class I G
(Di Nicola et al., 2002;Meisel et al., 2004; Aggarwal and Pittenger,
2005; Selmani et al., 2008; Choi et al., 2011). Extracellular vesicles
(EVs)—bilipid membrane-enclosed vesicles ranging from 50 nm
to a few µm in diameter—are also an important part of the
MSC secretome (Lener et al., 2015). Mesenchymal stromal cell-
derived extracellular vesicles (MSC-EVs) play a prominent role in
intercellular communication by allowing the horizontal transfer
of microRNAs (miRNAs), mRNAs, lncRNAs, proteins, lipids and
other bioactive molecules between MSCs and target cells (Rani
et al., 2015; Maas et al., 2017; van Niel et al., 2018).
So far, MSC-EVs have shown considerable therapeutic
potential as cell-free surrogates of MSC immunomodulation in
multiple disease models (Bruno et al., 2009; Lai et al., 2010).
MSC-EVs have also been tested in a patient with graft-versus-
host disease and in a patient cohort suffering from chronic kidney
disease, although further evidence is still needed to support their
widespread clinical use (Kordelas et al., 2014; Nassar et al., 2016).
However, despite the considerable momentum gained by MSC-
EV research, the precise mechanism by which MSC-EVs interact
with the immune system is still debated, since available evidence
is highly context-dependent and fragmentary, with a limited
number of reports trying to link their efficacy to specific active
components shuttled within them. An improved understanding
of MSC-EVs’ mechanism of action is therefore crucial to improve
and standardize these therapies. Furthermore, by enriching
MSC-EV cargo with certain bioactive molecules through specific
preconditioning protocols tailored to each disease and patient,
these strategies could potentially contribute to overcoming one
of themajor hurdles ofMSC-based therapeutics, which is variable
patient response (Wang et al., 2014a; Galipeau et al., 2016; Najar
et al., 2018; Noronha et al., 2019).
In this work, the currently available evidence on the molecular
mechanisms underlying MSC-EV cargo’s immunomodulatory
effects is reviewed. Although multiple reports have studied the
effects of MSC-EVs on the immune system, this concise
review selects and organizes studies that functionally
validate and pinpoint specific MSC-EV-borne mediators of
immunomodulation. The signaling events triggered by MSC-
EVs in target immune cells are highlighted. Reports that
study the effects of preconditioning in MSC-EV-mediated
immunomodulation are also presented, as well as the major
challenges that need to be addressed to harness the full potential
of these signaling vehicles and effectively bring MSC-EV
treatments to the clinic.




MSC-EVs have been traditionally classified as exosomes,
microvesicles, and apoptotic bodies (Giebel et al., 2017).
However, physical separation of MSC-EVs by this biogenesis-
based classification is not realistic given the current lack of
unequivocally or universally specific makers for each subtype
(Lötvall et al., 2014). For this reason, a recent position statement
from the International Society for Extracellular Vesicles
recommends to instead refer to EV subtypes using operational
terms, such as size, density, biochemical composition, or
descriptions of specific EV conditions or cell of origin (Théry
et al., 2018).
MSC-EV characterization should comprise multiple,
complementary techniques to rule out confounding factors and
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assure that observed biological effects are not due to co-isolated
materials (Théry et al., 2018). However, given the large number
of MSC sources, culture conditions, preconditioning protocols,
and EV isolation strategies, developing a one-size-fits-all solution
to define MSC-EVs is not feasible. As a minimum prerequisite,
MSC-EVs should derive from MSCs that meet the minimal
criteria from the International Society for Cell and Gene Therapy
(Dominici et al., 2006; Ramos et al., 2016; Witwer et al., 2019).
MSC-EV characterization should also include assessment of
MSC-EVs’ lipid to protein or RNA ratios, purity, integrity, and
cargo biological activity (Witwer et al., 2019).
Selective sorting mechanisms operate to enrich specific
RNAs, proteins and lipids within EVs (Anand et al., 2019).
Despite the aforementioned disparity of MSC-EV sources and
preparation methods, a common specific MSC-EV proteomic
signature has been recently proposed (Van Balkom et al., 2019).
Comprehensive overviews of the miRNA and lipidomic profiles
of MSC-EVs harvested from different tissue sources have also
been published (Baglio et al., 2015; Fang et al., 2016; Ferguson
et al., 2018; Kaur et al., 2018; Liu et al., 2019; Showalter et al.,
2019). As the field ofMSC-EV research grows, similar approaches
will be crucial to understand and characterize the profile of EVs
harvested from preconditioned MSCs.
MOLECULAR MEDIATORS OF THE
CROSS-TALK BETWEEN MESENCHYMAL
STROMAL CELL-DERIVED
EXTRACELLULAR VESICLES AND THE
IMMUNE SYSTEM
The majority of reports presented here focus on macrophages
(Figure 1), underscoring the need for further studies that dissect
these mechanisms in adaptive immunity. Interestingly, a recent
paper reported that MSCs’ immunomodulatory effects on B cells
were notmediated by secretedMSC-EVs (Carreras-Planella et al.,
2019). It is worth noting that the authors used size-exclusion
chromatography to isolate EVs, in contrast with most of the
works reviewed here, which rely on ultracentrifugation methods.
Previous reports have also suggested that MSC-EVs are not as
effective as their cellular counterparts (Conforti et al., 2014;
Gouveia-de-Andrade et al., 2015). This highlights the necessity
of greater standardization and reproducibility, given the variety
of cell sources, isolation and functional assays available (Théry
et al., 2018).
miRNAs
miRNAs are a subtype of small non-coding RNAs which interact
with target mRNA molecules to induce their degradation and
translational repression (O’Brien et al., 2018). miRNAs are
selectively sorted into EVs, in which they remain protected from
degradation (Li et al., 2012). Thus, miRNAs are delivered into
target cells with high efficiency, in which they exert biological
effects and regulate cell activity (Gallo et al., 2012; O’Brien
et al., 2018). Several miRNAs have been singled out as mediators
of the immunomodulatory effects of MSC-EVs on immune
populations, and are briefly summarized below.
Toll like receptor 4 (TLR4) and the MYD88 innate immune
signal transduction adaptor (MYD88)-dependent signaling
pathway are the focus of a significant number of studies that
analyze the effects of MSC-EV cargo on macrophage function.
This signaling pathway mediates macrophage activation upon
recognition of pathogen-associated molecular patterns such as
bacterial lipopolysaccharide (LPS) (Lu et al., 2008; Park and Lee,
2013). Downstream signaling effectors converge to nuclear factor
kappa B (NF-κB), which controls the expression of numerous
proinflammatory molecules and drives macrophages into a
M1 proinflammatory phenotype (Wang et al., 2014b). Several
miRNAs presented in this and the preconditioning sections of
the review target components of the TLR pathway. Among such
miRNAs are miR-21, miR-146a, miR-182 or miR-223, to cite
a few, which are enriched in MSC-EVs and act as negative
regulators of this pathway (O’Neill et al., 2011; Qin et al., 2018;
Curtale et al., 2019).
Murine MSC-EVs, enriched in miR-182-5p, have been shown
to reduce TLR4, MyD88 and NF-κB levels in macrophages and
induce polarization toward an M2 anti-inflammatory phenotype
(Zhao et al., 2019). These effects were recapitulated by a miR-
182 mimic and partially reversed upon miR-182 depletion in
MSC-EVs. In an in vivo murine model of myocardial damage,
the authors also showed that TLR4-deficient mice recapitulated
MSC-EV-mediated dampening of myocardial inflammation and
macrophages’ phenotype shift.
An additional study focusing on macrophage polarization
analyzed the role of MSC-EV-borne mir-223 (Wang et al.,
2015). Through loss-of-function studies, it was shown that
MSC-EVs from Mir223 knockout mice failed to reduce LPS-
induced cytokine production in macrophages. In turn, MSC-
EVs from wild type mice carrying miR-223-5p and -3p
inhibited this secretion. Furthermore, MSC-EVs dampened
systemic inflammatory response, reduced cardiac dysfunction
and increased survival in a murine model of polymicrobial sepsis,
while injection ofMSC-EVs fromMir223 knockout mice failed to
display these effects. Both miR-223-5p and -3p target numerous
inflammatory mediators and have recently emerged as a critical
factors in the pathogenesis of sepsis and inflammatory disease
(Haneklaus et al., 2013).
In a report by Liu et al. (2018), mouse MSC-EVs also
suppressed the secretion of proinflammatory mediators
by impeding the activation of the nucleotide-binding and
oligomerization domain-like receptor 3 (NLRP3) inflammasome
in macrophages both in vitro and in vivo. Recently, several
miRNAs have emerged as key regulators of the inflammasome,
among which miR-17 is included (Zamani et al., 2019). Enriched
in murine MSC-EVs, miR-17 was shown to reduce TXNIP levels,
a key mediator of NLRP3 inflammasome activation. Disease
amelioration and decreased NLRP3, caspase 1, IL-1ß and IL-18
levels were observed upon MSC-EV treatment. The observed in
vitro and in vivo effects in macrophages were abrogated upon
miR-17 knockdown in MSC-EVs.
miR-21-5p, highly enriched in human MSC-EVs, was
pinpointed as a potential mediator of human MSC-EVs’
impairment of dendritic cells’ migration ability in vitro
(Reis et al., 2018). MSC-EV-borne miR-21-5p decreased
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FIGURE 1 | Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs): cargo’s effects on macrophages. A simplified overview of the main effects triggered
by MSC-EV cargo in macrophages–which are the focus of the majority of reviewed studies–is presented. MSC-EVs are isolated from cultured cells, which can be
pre-conditioned with different strategies to increase their immunomodulatory potential. Details of the effector molecules, signaling pathways and mediated
immunological effects are presented in the main text. ANGPT1, angiopoietin 1; CCR2, membrane receptor chemokine (C-C motif) receptor 2; miRNA, microRNA;
MSC, mesenchymal stromal cell; MSC-EV, mesenchymal stromal cell-derived extracellular vesicle; TLR, toll like receptor. Created with BioRender.com.
dendritic cells’ CCR7 levels, a chemokine receptor with a
crucial role in mature dendritic cell lymph node homing
(Comerford et al., 2013). In this study, MSC-EVs also reduced
antigen uptake in immature dendritic cells, limited their
maturation and activation and increased anti-inflammatory
cytokine production.
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Corneal MSC-EVs were shown to reduce corneal neutrophil
infiltration and fibrotic gene expression after wounding (Shojaati
et al., 2019). However, MSC-EVs’ regenerative capabilities were
hampered following knockdown of Alix, a component of the
miRNA EV-packaging system. This evidence, together with
previous studies on liver fibrosis and inflammation, underscores
the role of MSC-EV-borne miRNAs as mediators of MSC-EVs’
interactions with the extracellular matrix, fibrosis, and scarring
(Qiu et al., 2018).
mRNAs
Horizontal mRNA transfer mediated by MSC-EVs has recently
emerged as a mechanism of paracrine exchange of genetic
information by MSCs (Tomasoni et al., 2013; Ragni et al., 2017).
These studies demonstrated effective horizontal mRNA transfer
by MSC-EVs and subsequent translation in recipient cells, thus
conferring new functionality. These findings are supported by the
notion thatMSC-EVs display a specificmRNA profile rather than
just a random subset of expressed genes (Bruno et al., 2009; Ragni
et al., 2017).
In a murine model of LPS-induced acute lung injury,
experimental data suggested that human MSC-EV-transferred
fibroblast growth factor 7 (FGF7, also known as keratinocyte
growth factor) mRNA could mediate the therapeutic effects of
MSCs. FGF7 mRNA transfer and subsequent translation into
human FGF7 protein contributed to a decrease in neutrophil
influx and chemokine (C-X-C motif) ligand 2 (CXCL2) levels in
the bronchoalveolar lavage fluid (BALF) (Zhu et al., 2014). It is
worth noting that FGF7 is one themost highly enrichedmRNA in
humanMSC-EVs (Ragni et al., 2017). Indeed, the effects on acute
lung injury were partially negated following MSC pretreatment
with siRNA against FGF7. However, in this study, whether FGF7
mRNA directly targeted the lung epithelium or inflammatory
cells remained unanswered.
In the context of MSC-EVs’ immunomodulatory effects
on immune populations, a subsequent study by the same
group demonstrated that angiopoietin 1 (ANGPT1) mRNA
in MSC-EVs mediated an increase in IL-10 and a decrease
in TNF-alpha in macrophages in vitro (Tang et al., 2017).
This effect was lost in EVs derived from MSCs transfected
with shRNA against ANGPT1, thus demonstrating a role
for mRNA transfer in the crosstalk between MSC-EVs
and immune cells. Reminiscent of the first study, MSC-
EVs also reduced neutrophil influx and CXCL2 levels in
the BALF of mice with LPS-induced acute lung injury.
In contrast, ANGPT1 mRNA-deficient MSC-EVs failed to
do so.
Proteins
MSC-EVs are endorsed with functional surface proteins and
may also modulate target cells by delivering intracellular
proteins. Among the first group of molecules is the
membrane receptor chemokine (C-C motif) receptor 2
(CCR2), enriched in murine MSC-EVs. It has been suggested
that MSC-EV-borne CCR2 acts as a decoy to bind and
reduce free extracellular C-C motif chemokine ligand 2
(CCL2) levels and function (Shen et al., 2016). MSC-EV
treatment blocked CCL2 effects on macrophage recruitment,
induction of NF-κB signaling and subsequent expression of
proinflammatory cytokines.
TSG-6 was also validated as a one of the protein mediators of
MSC-EV immunomodulation in a murine model of hyperoxia-
induced lung injury. MSC-EV-induced decrease in neutrophil
infiltration in BALF was negated by neutralizing anti-TSG-6
antibodies and by siRNA knockdown of TSG-6 within vesicles
(Chaubey et al., 2018).
Inflammation-stimulated MSC-EVs were also found to
be enriched in cyclooxygenase 2 (COX2), which might
contribute to a local increase in PGE2 (Harting et al., 2018).
Moreover, MSC-EVs treated with COX2 inhibitors displayed
reduced anti-inflammatory capabilities in an in vitro TNF-alpha
production assay.
Mitochondria
Intriguingly, mitochondrial transfer to target cells has
been recently identified as a mediator of MSCs’ biological
effects (Spees et al., 2006; Otsu et al., 2009; Islam et al.,
2012; Konari et al., 2019). In particular, MSC-EV-mediated
mitochondrial transfer enhanced oxidative phosphorylation
in macrophages, which resulted in a reduction of their
proinflammatory cytokine secretion and increased phagocytic
capacity (Morrison et al., 2017). Phinney et al. (2015) provided
further evidence that macrophages could engulf MSC-EV-
borne mitochondria, which in turn enhanced macrophage
bioenergetics. Collectively, these studies suggest a role for
MSC-EV-mediated mitochondrial transfer in the modulation of




VESICLE CARGO AND IMPROVES ITS
THERAPEUTIC EFFECTS
The immunosuppressive properties of MSCs are
deeply influenced by the stimuli present in their local
microenvironment, and the nature of these signals
fundamentally determines the immunomodulatory effects
of MSCs (Ren et al., 2008; Wang et al., 2014a; Najar et al.,
2018). This context-dependency is endorsed by the fact
that MSCs display increased efficacy in preclinical models
of established inflammatory disease compared to their
preventive administration before inflammation develops
(Sudres et al., 2006; Shi et al., 2012). For this reason, several
strategies have been proposed in order to precondition
MSCs and improve their therapeutic potential, including
proinflammatory cytokines, hypoxia, or chemical compounds
(Najar et al., 2018; Noronha et al., 2019). These strategies
aim to recapitulate the microenvironment to which MSCs
are exposed upon infusion in patients with systemic
inflammation or altered immune responses (Galipeau
et al., 2016). As expected, the MSC secretome and MSC-
EVs are also affected by preconditioning strategies, which
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modulate their cargo and immunosuppressive properties
(Domenis et al., 2018; Ferreira et al., 2018; Harting et al., 2018,
Showalter et al., 2019).
Multiple studies have demonstrated that preconditioned
MSC-EVs display an increased ability to induce an M2 anti-
inflammatory phenotype in macrophages compared to basal
MSC-EVs. As such, Domenis et al. (2018) reported that priming
human MSCs with proinflammatory cytokines IFN-gamma and
TNF-alpha favored this effect in MSC-EVs. Specific miRNAs
involved in macrophage polarization were enriched in MSC-
EVs following inflammatory preconditioning, among which
stood miR-34a-5p, miR-146a-5p, and miR-21-5p. Interleukin
1 receptor associated kinase 1 (IRAK1), a signaling mediator
of the MyD88 signaling pathway targeted by miR-146a, was
strongly downregulated upon treatment with preconditioned
MSC-EVs. Further functional studies will help understand
the individual contribution of each identified miRNA to the
observed effects.
Human MSC-EV-borne miR-146a was also the focus of Song
et al. (2017), who observed that this miRNA was particularly
enriched in IL-1ß-primedMSC-EVs. PrimedMSC-EVs delivered
miR-146a into macrophages, increased M2 markers IL-10 and
Arg1 mRNA, and decreased M1 markers TNF-alpha and
Nos2 (iNOS) mRNA in a greater extent that basal MSC-EVs.
These effects were lost in IL-1ß-primed MSC-EVs previously
transfected with miR-146a inhibitors, underscoring the role of
miR-146a in M2 polarization by IL-1ß-primed MSC-EVs.
Increased M2 polarization capacity was also observed in EVs
from LPS preconditioned MSCs. In this regard, the work from Ti
et al. (2015) uncovered let-7b as the highest uniquely-expressed
miRNA in human MSC-EVs with this priming strategy. let-7b
regulated macrophage polarization through TLR4 and NF-κB
subunit p65 downregulation and signal transducer and activator
of transcription 3 (STAT3) and AKT upregulation.
Various studies focused on the influence of hypoxia in
the mechanism of action of MSC-EV cargo. Lo Sicco et al.
(2017) demonstrated that EVs from human MSCs cultured
under hypoxic conditions displayed an increased ability to
induce murine M2 anti-inflammatory macrophages compared
to basal MSC-EVs. miR-223 and miR-146b stood out among
over-expressed miRNAs in hypoxia-preconditioned MSC-EVs.
Ren et al. (2019) provided further evidence that hypoxia-
preconditioned human MSC-EVs favor human macrophage M2
polarization in comparison to their normoxic counterparts. In
their study, they showed that miR-21-5p knockdown abrogated
these effects, likely mediated by phosphatase and tensin homolog
(PTEN) downregulation, which in turn released its blockage
of AKT and STAT3 activation. These effects were maintained
in vivo and partially mediated by miR-21-5p, which had been
previously shown to be enriched in hypoxia-preconditioned
murine MSC-EVs (Cui et al., 2018). Hypoxia is one of the
hallmarks of tissue damage, and its use in MSC preconditioning
might mimic the microenvironment to which MSCs are exposed
in vivo (Ferreira et al., 2018).
CLOSING REMARKS: THE ROAD TOWARD
CLINICAL-GRADE, CELL-FREE
THERAPEUTICS
The generalized use of clinical-grade MSC-EVs is still far from
becoming a reality, based on a number of challenges that
need to be solved in the coming years. One of the main
limitations for the use of EVs is the low yield of particles
obtained with current technologies used for EV isolation
and purification, resulting in insufficient EV numbers for
clinical purposes (Haraszti et al., 2018; Paganini et al., 2019).
The use of spinner-flasks containing different microcarriers
that retain MSCs is one of the most extended options to
increase MSC numbers, together with the use of hollow-fiber
bioreactors, which can anchor up to 100-fold higher MSCs
than conventional flasks (Lu et al., 2017; Cha et al., 2018;
Phan et al., 2018). Alternative EV isolation techniques, some
of which can be scalable and potentially GMP compatible, can
potentially increase MSC-EV recovery (Watson et al., 2018,
Paganini et al., 2019).
The multiple immunomodulatory signaling capabilities
presented in the previous sections show MSC-EVs’ immense
potential for the treatment of immune disorders. MSC are
considered advanced-therapy medical products (ATMP) by
regulatory agencies (Lener et al., 2015). In contrast, given
their cell-free nature, MSC-EVs are not subject to complex
ATMP regulations and do not carry the risk of carcinogenic
potential transformation. Due to their size, they are able
to traverse the blood-brain barrier and other physiological
interfaces. Finally, MSC-EVs are easily handled and stored
and remain stable for extended periods of time (Rani et al.,
2015; Maas et al., 2017; Sharma et al., 2017). Such potential
advantages make MSC-EVs promising candidates for future
therapeutic applications.
The studies summarized in this work support the claim
that the fundamental mechanism of action of MSC-EVs lies
in their ability to transmit biological information between
cells. Although multiple candidates within MSC-EV cargo
have been presented as mediators of their therapeutic effects,
many operate through similar pathways and mechanisms of
action, warranting further investigations that dissect their
individual contribution. These studies are the starting point
for the future development of engineered MSC-EVs and
targeted preconditioning protocols, which could potentially
enrich MSC-EVs with relevant immunomodulatory effectors
and thus broaden their therapeutic capabilities in immune
system disorders.
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